Psychopharmacology

Learn how to prevent and spot tardive dyskinesia from antipsychotics, track key risk factors, and treat symptoms with VMAT2 inhibitors.

A fast-tracked once-daily pill aims to ease cannabis withdrawal by restoring CB1 signaling and reward-pathway balance as phase 3 enrollment surges.

Learn how the inhibition constant and 5-HT2A binding explain LSD effects—and why potent atypical antipsychotics may rapidly end a bad trip.

FDA hearing spotlights debates over psychedelic therapy: who administers, how to prove efficacy, and how to track safety as approvals near.

Experts dissect 10 common antidepressant myths, separating evidence from fear on efficacy, addiction, suicide risk, withdrawal, and safe tapering.

Phase 1 driving simulation finds bedtime GlyphAllo for major depressive disorder shows no next-morning driving impairment, while advancing allopregnanolone-based oral treatment development.

Clinicians learn how to assess and treat sexual dysfunction in depression, menopause, and psych meds—plus drug options that preserve desire and arousal.

Review the developments in GLP-1s in 2026.

Learn how gene variants shape CYP450 metabolism, receptors, and transporters—explaining intermediate phenotypes that influence psychiatric medication response.

Why benzodiazepines still anchor acute anxiety care: when short-term use fits, how to spot red flags, and taper safely.

Experts weigh benzodiazepine benefits, dependence myths, and safer prescribing in older adults, including what evidence really says about Alzheimer risk.

Nardin Valetin, DO, explains how to spot hormonally driven mood symptoms in perimenopause and when HRT can support psychiatric treatment.

Experts unpack benzodiazepines in seniors: Beers Criteria, fall risk, Alzheimer bias, and practical low-dose, mindful prescribing strategies.

Clinicians weigh benzodiazepine benefits against dependence fears, with expert guidance on safe prescribing, withdrawal tapering, and long-term anxiety treatment choices.

Learn more about ADHD across populations in this podcast episode.

Explore why combining medication and psychotherapy often improves major depression outcomes, plus the latest debates on treatment sequencing and public trust in psychiatry.

Psychiatrists admit carrying benzos for travel sleep or anxiety; learn why experts say occasional use differs from dependence and withdrawal risk.

HLP003, a deuterated psilocin agonist, enters phase 3 as an add-on for MDD, aiming to boost SSRI/SNRI response earlier.

A quick recap of the last week in psychiatric news.

From tricyclics to esketamine, Ron Pies, MD, explains antidepressant progress and why precise diagnosis matters when treating today’s diverse depression.

FDA approves PET imaging agent for Alzheimer disease tau pathology.

Psychiatrists rebut antidepressant myths, outlining modest benefits, real but manageable risks, and why slow tapering matters for withdrawal.

Real‑world inpatient use of xanomeline/trospium shows rapid awakening from negative symptoms in schizophrenia, with response predictors and striking case insights.

New data on viloxazine ER (Qelbree) show improvements in ADHD, depression, and anxiety in adults, including those who use nicotine or cannabis.

KINECT-PRO shows Ingrezza eases tardive dyskinesia movements and boosts daily function and quality of life, even across psychiatric diagnoses.